Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

NCT07401615 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-11-25
Last updated
2026-02-12

Condition(s) studied

Non Small Cell Lung CancerPulmonary Stereotactic Radiotherapy

Study summary

Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation.

When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time.

Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Inoperable primary non-small cell lung cancer or other metastatic primaries with lung metastases, already treated with radical dose SBRT * Inoperable local recurrence (defined as a tumor recurrence overlapping the 50% isodose field) confirmed by documented radiographic findings and/or pathological biopsies within the thoracic area * Patients had previously received curative intent SBRT with a biologically equivalent dose equal or higher than 75 Gy * Stereotactic reirradiation with ablative purposes up to 8 fractions * No active distant metastasis or controlled distant metastasis at the time of re-irradiation * More than 12 months from previous SBRT * PS ≤ 2 Exclusion Criteria: * Previous conventional RT * Reirradiation with palliative doses * Reirradiation with conventionally fractionated or mildly hypofractionated RT

Primary outcome measure(s)

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — from treatment to 1 years follow up
    evaluation of treatment safety through toxicities according to the CACTE scale

Trial sites (11)

FacilityCityRegionStatus
AST Papa Giovanni XXIII Bergamo Bergamo Recruiting
Radiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi Bologna Bologna Not Yet Recruiting
REM Radioterapia Catania Catania Not Yet Recruiting
Radiation oncology unit, Ospedale San Raffaele Milan Milano Not Yet Recruiting
Radiotherapy Department, Istituto Europeo di Oncologia Milan Milano Not Yet Recruiting
IRCCS Humanitas Research Hospital Rozzano Milano Recruiting
Radiotherapy Department, IRCCS Istituto Nazionale Fondazione G. Pascale Naples Napoli Not Yet Recruiting
Centro Fondazione Policlinico Universitario "A. Gemelli", Radioterapia Oncologica Roma Roma Not Yet Recruiting
Radioterapia Oncologica - Ospedale dell'Angelo Venezia Venezia Not Yet Recruiting
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center Negrar Verona Not Yet Recruiting
AOUI Verona, DAI Chirurgia e Oncologia - Radioterapia Oncologica Verona Verona Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07401615 on ClinicalTrials.gov ↗ ← All trials in Italy